从研发实力来看，Summit Therapeutics在肿瘤免疫领域深耕多年，研发团队阵容强大，具备丰富的新药研发经验，能有力推动ivonescimab后续的临床研究和开发。从市场竞争角度，当前肺癌治疗领域虽竞争激烈，但ivonescimab独特的双靶点作用机制使其脱颖而出，有望在众多竞品中抢占较大市场份额。且公司与康方生物的合作优势互补，整合双方资源与渠道，加速药物商业化。此外，SMMT当前市值194.63亿，股价26.2美元，市值和股价仍有上升空间，极具投资价值。我沽出認沽期權做好！
| Side | Price | Filled | Realized P&L |
|---|---|---|
| Sell Open | 0.40 3Lot(s) | -- Closed |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- JimmyTurner·2025-08-23Great potentialLikeReport